Related Experiment Video
Updated: Jun 16, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Anti-androgen treatments.
Anne Bachelot1, Nathalie Chabbert-Buffet, Sylvie Salenave
1Service d'endocrinologie et médecine de la reproduction, groupe hospitalier Pitié-Salpêtrière, Paris, France. anne.bachelot@psp.ap-hop-paris.fr
Annales D'Endocrinologie
|January 26, 2010
Summary
Estrogen plus progestin contraceptives and cyproterone acetate are first-line treatments for moderate to severe hirsutism in women. Spironolactone and other therapies are considered for second or third-line use, with laser hair removal as a long-term option.
Area of Science:
- Endocrinology
- Dermatology
- Pharmacology
Background:
- Hirsutism and acne are common concerns for women of childbearing age.
- Effective anti-androgen therapies are crucial for managing these conditions.
Purpose of the Study:
- To outline the first-line, second-line, and third-line therapeutic options for hirsutism in women.
- To clarify the role of various pharmacological and non-pharmacological treatments.
Main Methods:
- Review of current clinical guidelines and evidence for hirsutism treatment.
- Categorization of treatments based on efficacy and line of therapy.
Main Results:
- Estrogen plus progestin contraceptives (EPP) and cyproterone acetate (CPA) with estrogen are first-line treatments for moderate to severe hirsutism.
- Spironolactone is a second-line option, while flutamide and finasteride are third-line therapies.
- GnRH analogs are not indicated, and long-term hair removal (electrolysis, laser) is a supplementary treatment.
Conclusions:
- A stepwise approach to hirsutism management is recommended, starting with EPP or CPA.
- Hormonal therapies and hair removal methods offer various options for patients with hirsutism.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Testosterone: Functions and Regulation
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...